4.4 Article

Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol

期刊

OPEN FORUM INFECTIOUS DISEASES
卷 7, 期 5, 页码 -

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofaa150

关键词

Acinetobacter baumannii; antimicrobial resistance; cefiderocol; osteomyelitis

资金

  1. National Institutes of Health [K24-AI093969]
  2. MedImmune
  3. Cerexa/Forest/Actavis/Allergan
  4. Pfizer
  5. Advanced Liquid Logics
  6. Theravance
  7. Novartis
  8. Cubist/Merck
  9. Medical Biosurfaces
  10. Locus
  11. Affinergy
  12. Contrafect
  13. Karius
  14. Genentech
  15. Regeneron
  16. Basilea

向作者/读者索取更多资源

Cefiderocol is a novel catechol siderophore cephalosporin antibiotic developed to treat resistant gram-negative infections. We describe its successful use as rescue therapy, combined with surgical debridement, to treat a patient with osteomyelitis due to extensively drug-resistant Acinetobacter baumannii. Bacterial whole-genome sequencing identified the strain and antibiotic resistance determinants.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据